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Abstract
Background Alzheimer’s disease (AD) is associated with
considerable costs and has a significant impact on health
and social care systems.
Objective This study assessed whether baseline comor-
bidities present in 2,594 patients with AD participating in
two semagacestat randomized placebo-controlled trials
(RCTs) would significantly impact overall costs.
Methods Resource utilization was captured using the
Resource Utilization in Dementia Scale-Lite. Comorbidi-
ties and concomitant medications were tabulated via
patient and caregiver reports. Only baseline data were
analyzed. Direct and indirect costs per month were calcu-
lated per patient. The relationship between cost and
explanatory variables was explored in a regression model.
Results The baseline monthly cost of care in this RCT
population was £1,147 ± 2,483, with informal care costs
accounting for 75 % of costs. Gender, age, and functional
status were significant predictors of costs (p B 0.0001).
The cost ratio was not impacted when the number of
comorbidities was added to the model (cost ratio = 0.95;
95 % CI 0.91–0.99) or when combined with the number of
concomitant medications (cost ratio = 0.97; 95 % CI
0.95–1.00). Inconsistent findings related to the impact of
individual comorbidities on costs were noted in sensitivity
analyses.
Conclusions The number of comorbidities, alone or when
combined with concomitant medications, did not impact
baseline costs of care, perhaps because RCTs often enroll
less severely ill and more medically stable patients. How-
ever, higher costs were consistently associated with greater
functional impairment similar to non-RCT databases.
Supplemental sources (e.g., claims databases) are likely
needed to better estimate the effects of disease and treat-
ment on costs of illness captured in RCTs for AD.
Keywords Alzheimer’s disease  Randomized controlled
trials  Semagacestat  Comorbidities  Concomitant
medications  Economics
JEL Classification I120 (health production)  C900
(design of experiments)
Introduction
Alzheimer’s disease (AD) is progressive neurological dis-
order that is thought to be the causal pathology in roughly
70 % of dementia cases [1]. AD is a considerable and
growing public health issue with a significant impact on
health and social care systems [1, 2]. The estimated costs of
caring for patients with dementia worldwide in 2010
reached $604 billion [3], and those figures are expected to
continue rising as the world population ages [3, 4].
Patients with AD incur far greater costs (inpatient and
outpatient care and prescriptions) than their cohorts with-
out AD. For patients with AD, inpatient stays and
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institutionalization account for the majority of direct care
costs [5, 6]. Additionally, the informal care costs (e.g.,
number of annual unpaid care hours per unprofessional
caregiver) of patients living in the community represent a
substantial proportion of overall costs of care [5, 7, 8].
Costs are influenced by a variety of factors, including
severity of the illness [7, 9] and patient comorbidities [5, 9–
13]. Patients with dementia or AD typically have more
comorbidities than matched controls [11, 13]. The most
common comorbidities include psychiatric (specifically
depression), diabetes and other endocrine/metabolic dis-
orders, cerebrovascular and cardiovascular disease, gas-
trointestinal disorders, urogenital disorders, and hip
fractures [12–15]. These comorbidities, either alone or
through interactive effects with dementia/AD, in addition
to the prescription cost for treatment of non-AD illnesses,
contribute to the overall greater cost associated with AD.
Furthermore, it has been demonstrated that the care costs of
patients with AD increase with greater dementia severity
[5, 8, 12, 13].
Considerable efforts are underway to find new treat-
ments that will modify the underlying pathological process
of AD [1]. While regulatory evaluations of new AD
treatments will focus on safety and efficacy [2, 4], eco-
nomic data and cost-effectiveness modeling techniques are
needed to inform payer evaluations.
Given the difficulties in capturing costs of care in par-
allel with clinical measures over a substantial period of
time to test disease-modifying agents, previous cost-
effectiveness analyses of AD therapies have relied on
multiple data sources [16–18]. Cost-of-illness and disease
progression data from sources external to the randomized
controlled trials (RCTs) have been used in combination
with efficacy findings from RCTs [18]. These cost sources
included observational studies as well as administrative
claims databases [3]. Ideally, economic data would be
incorporated into clinical trials, particularly as more recent
trials of disease-modifying treatments for AD span
18 months. For instance, Gustavsson et al. [19] used pla-
cebo data from a negative, 18-month trial of an ostensible
AD disease modifier to examine predictors of care costs,
excluding comorbidities and concomitant medications.
Their findings demonstrated similar patterns to what is
commonly seen in non-RCT studies, which is that a greater
degree of functional, cognitive, and behavioral impairment
was significantly associated with higher and increasing
costs over time [19]. Care costs also increased over time. A
better understanding of the comorbid conditions in the
RCT population and their potential impact on care costs
may provide greater insight into the effectiveness of
treatments for chronic diseases like AD and more accurate
estimations of the costs associated with the overall disease
state and treatment [20].
The present analyses used baseline data from a discon-
tinued clinical trial to examine how comorbidities would
impact costs of illness, as assessed in the trial. It was
hypothesized that that the comorbidity profile would have a
significant impact on overall costs, similar to patterns seen
in observational and retrospective claims analyses. If the
hypothesis is valid, evaluating the type of comorbidities at
baseline and over time in clinical trials may be an impor-
tant added covariate in assessing the overall impact of
future pharmacotherapeutic candidates on costs.
Methods
The present analyses used baseline data from two similarly
designed 88-week RCTs of semagacestat [H6L-MC-LFAN
(IDENTITY) and H6L-MC-LFBC (IDENTITY-2)], a
gamma-secretase inhibitor AD drug candidate previously
in development, in patients with mild-to-moderate
dementia due to AD [21]. Further methodological details
for the H6L-MC-LFAN and H6L-MC-LFBC trials were




The experimental treatment was discontinued early due to
safety findings. The protocols were subsequently amended
prior to completion in order to allow for continued safety
monitoring of patients [21]. As a result of the early dis-
continuation of study drug and subsequent protocol
amendments necessitating the change of the study design,
the current analysis in this paper relied on baseline data
only (with data from both the treatment and placebo arms
included). Between the two studies, clinical trials were
conducted in 31 countries. Randomized patients met cri-
teria for probable AD according to the National Institute of
Neurological and Communicative Disease and Stroke/
Alzheimer’s Disease and Related Disorders Association
(NINCDS-ADRDA) guidelines and were in the mild-to-
moderate stage of dementia severity as measured by the
Mini-Mental State Examination (MMSE 16–26, inclusive).
Assessment of inclusion/exclusion criteria was based on
patient age (C55 years), patient and caregiver reports,
investigator assessment, and medical records if available.
Relevant to the present analyses, patients were excluded if
they suffered from life-threatening or serious chronic ill-
nesses, or unstable illness (e.g., significant active cardiac
disease, uncontrolled hypertension, uncompensated con-
gestive heart failure, endocarditis, or end-stage renal dis-
ease) which, in the opinion of the investigator, would
interfere with assessment of safety and efficacy or that
would result in a life expectancy of less than 2 years.
Patients were required to have a reliable caregiver familiar
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with their health and functional status. Informed consent
was obtained from all participants or their legal represen-
tatives prior to study enrollment. The studies were con-
ducted according to the Declaration of Helsinki and were
approved by local independent review boards in all
countries.
Co-primary efficacy measures for the trial were the
11-item Alzheimer’s Disease Assessment Scale-Cognitive
Subscale (ADAS-Cog) [22, 23] and the Alzheimer’s Dis-
ease Cooperative Study-Activities of Daily Living Scale
(ADCS-ADL) [24, 25] for functional ability. Additional
outcome measures included in the trials were the Mini-
Mental State Examination (MMSE) [26], Clinical
Dementia Rating (CDR) scale [27, 28], Neuropsychiatric
Inventory (NPI) [29], and EuroQol 5-Dimension (EQ-5D)
[21, 30].
Resource utilization was assessed by the Resource Uti-
lization in Dementia-Lite (RUD-Lite) scale [31, 32]. This
scale includes a structured interview completed with the
AD patient and their caregiver to assess healthcare resource
utilization of patients and their caregivers. In these studies,
caregivers provided information on the RUD-Lite regard-
ing the number of hours (in the past month, at baseline) that
care was provided to help the patient with basic (e.g.,
eating, dressing, etc.) and instrumental activities of daily
living (ADLs; e.g., shopping, cooking, etc.), as well as the
number of hours spent supervising the patient. Additional
resource utilization measures assessed included the number
of hospital visits, living accommodations (e.g., nursing
home placement), and use of community resources.
Patient comorbidities and concomitant medications at
baseline were assessed primarily via patient and caregiver
reports at study entry as well as via medical records, when
available. Individual drugs were grouped according to drug
class to facilitate reporting. Specific comorbidities were
chosen for inclusion in the subsequent analyses that rep-
resented common age-related comorbidities in the study
population most likely to be afflicted with AD; concomi-
tant medications were selected based on the most fre-
quently identified comorbid conditions.
Analyses
Only baseline data were analyzed and are presented.
Summary statistics for the clinical scales and the profile of
comorbidities and number of concomitant medications
were generated. Although study inclusion criteria defined
mild-to-moderate dementia severity by an MMSE score
ranging from 16 to 26, the scores at baseline reflected a
much broader range. Accordingly, dementia severity in the
analyses herein was categorized as mild (20–30), moderate
(10–19), and severe (0–9) using the standard convention.
Mean resource utilization captured by the RUD-Lite, cat-
egorized by type of resource, was tabulated. Baseline
report of caregiver time spent on personal ADLs, instru-
mental ADLs, and supervision in the past month is pre-
sented as mean hours per month and aggregated into a
mean of total informal care time spent per month. The total
caregiver time was capped at 540 h per month (18 h/day)
to avoid overestimation. Each type of accommodation and
hospitalization is presented as mean number of days per
month, and community care is presented as hours per
month.
Direct and indirect costs per month were calculated for
each patient in the study. All cost calculations were based
multiplying RUD-Lite resource utilization unit estimates
by published reimbursement costs in the United Kingdom
(UK) (Table 1) to allow for a common metric across
countries and to allow for comparison to recent publica-
tions on cost of illness [8]. A sensitivity analysis of the unit
costs from the United States (US) was performed to con-
firm if the factors were associated with the resource use or
the cost of those services. The model results for the US
were generally consistent with UK costs (results not
Table 1 Unit costs (UK British Pound Sterling)
Resource Unit cost (£, 2011)
Informal care (per hour)
Lost productiona 12.03
Lost leisure timeb 4.21
Accommodation (per night)c
Intermediate forms of accommodation 60.00
Dementia-specific residential accommodation 71.00






Community care services (per/hour/session/item)c
District nurse home visit, per hour 73.00
Home support worker/home care, per hour 29.00
Day care, per session 36.00
Home-delivered meals, per meal 5.00
Transportation, per rided 8.15e
a Estimated at the mean hourly gross pay for full-time employees in
the UK [33] plus an 8 % average employer pension contribution
according to FSTE 100 [34]
b Lost leisure time based on 35 % of gross average wage rate [35]
c Cost of hospitalization (per night) based on hospital ward of service
[36]
d Rates of taxi and private hire vehicle [37]
e Inflated from 1999 year price levels to 2011 year price levels by
overall consumer price index [37, 38]
Impact of comorbidities on costs in Alzheimer’s disease clinical trials 997
123
shown). The direct costs were based on the use of
accommodation (intermediate housing, dementia-specific
residential housing, long-term institutionalization), hospi-
talizations (geriatric, psychiatric, internal medicine, and
surgery), and community care visits (district nurse, home-
support worker, home-delivered meals, transportation, and
day care). Indirect costs were based on cost of caregiver
lost production calculated as the unadjusted sum of
instrumental and personal activities of daily living with a
maximum of 540 h (employed cut-off of 65 years of age)
and at the value of leisure time (retired/not employed).
Missing data were excluded from all statistics (e.g., sample
size, percentage, mean, standard deviation) in all tables.
Cost analyses were based on the whole patient population.
For regressions, if any of the covariates were missing, the
entire observation was ignored.
Differences in mean costs between patient subgroups
were tested for statistical significance using unpaired
t tests.
A cluster analysis using the Ward’s method of minimum
variance to cluster countries with similar baseline health-
care costs was performed to examine potential differences
in cost structures between countries. Due to the high
number of countries missing at least one cost component,
countries were clustered based on total monthly costs per
patient. Results from an RCT do not need a cluster
adjustment. However, the potential effect due to the clus-
tering of patients within a site was considered. This, in
combination with the small number of patients within each
site, suggested that there was no need for a clustering
adjustment.
The relationship between cost of care and explanatory
variables was explored in a regression model to determine
the drivers of cost of care. Cost and resource data are
usually of a distribution that constitutes of large number of
zero observations, no negative observations, and a few very
high observations. Cost functions are therefore estimated
with a generalized linear model (GLM) [30]. The GLM
gamma model with a log link was fitted using the maxi-
mum likelihood approach and was used to estimate the cost
function. A sensitivity analysis using an ordinary least-
squares approach yielded similar results (results not
shown).
Comorbidities, the number of comorbidities, and the
number of concomitant medications, including AD medi-
cations, were the covariates to impact costs. Adjustment
variables added to the costs model included demographics
of the patient (age, gender), cognitive (MMSE), functional
(ADCS-ADL), behavioral (NPI), and global (CDR, CDR-
SB) disease indicators. The comorbidities selected as
potential predictors included cancer, chronic obstructive
pulmonary disease, depression, diabetes, hyperlipidemia,
hypertension, cardiac ischemia, urinary tract infection,
epilepsy, and stroke. Individual comorbidities were selec-
ted to represent common age-related comorbidities and to
facilitate comparison to other samples (e.g., ICTUS
observational study [14]).
Results
A total of 2,594 patients were included at baseline, 55 %
were female with a mean age of 73 ± 8 years. As shown in
Table 2, at baseline, 61 % of patients had mild dementia
(MMSE 20–30), 32 % were in the least impaired quartile
of ADL ability (ADCS-ADL 68–78), 64 % had a low
number of neuropsychiatric symptoms (NPI\ 10), and
approximately 87 % were rated as mild on a global per-
formance scale (CDR 0.5–1). Of note, although the pro-
tocol inclusion requirement restricted enrollment to
patients with mild-to-moderate dementia at the screening
visit, one patient did score in the severe dementia range at
Table 2 Baseline demographics and by instruments
Demographics Total (N = 2,594)
Male, n 1,161 (44.76 %)
Age, mean (SD)a 73.26 (7.86)
Disease severity measure n %
MMSE, mean score (SD) 20.68 (3.45)
Mild (20–30) 1,594 61.47
Moderate (10–19) 998 38.49
Severe (0–9) 1 0.04
ADCS-ADL, mean score (SD) 58.48 (13.96)
68–78 (least dependent) 816 31.57
58–67 743 28.74
46–57 556 21.51
0–45 (most dependent) 470 18.18
NPI, mean score (SD) 9.59 (10.72)
High (C10) 942 36.48
Low (\10) 1,640 63.52
CDR, mean score (SD) 0.95 (0.49)
Mild (0.5–1) 2,236 86.70
Moderate (2) 333 12.91
Severe (3) 10 0.39
CDR-SB, mean score (SD) 5.61 (2.84)
Mild (0.5–9) 2,284 88.46
Moderate (9.5–15.5) 295 11.43
Severe (16–18) 3 0.12
ADCS-ADL Alzheimer’s Disease Cooperative Study-Activities of
Daily Living, CDR Clinical Dementia Rating, CDR-SB Clinical
Dementia Rating–Sum of Boxes, dimensions, MMSE Mini-Mental
State Examination, N overall sample size, n number of patients in
category, NPI Neuropsychiatric Inventory, SD standard deviation
a Age breakdown in years includes: 55–64 (n = 444), 65–74
(n = 961), and C75 (n = 1,188)
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the baseline study visit and was included in all analyses. Of
the comorbidities included in the analyses, hypertension
and hyperlipidemia were most commonly observed. Nearly
all patients (94 %) in this RCT population were taking at
least one medication inclusive of those for AD (Table 3).
The baseline monthly cost of care in this RCT popula-
tion was £1,147 ± 2,483 for which informal care costs
accounted for 75 % of costs (Table 4). Total costs per
patient per month stratified by gender and age were
numerically greater for females than males (£1,247 vs.
£1,023) and numerically greater for patients 75 years and
older (£1,352 for 75 ? years, £832 for 65–74 years, and
£1,281 for 55–64 years).
The individual effects of patient demographics and
disease severity on total costs of care were estimated in a
cost model using gamma model distribution with a log link.
Gender, age, and functional status were all significant
predictors of costs (p B 0.01). In this RCT population, age
was a significant variable associated with baseline total
costs of care. Patients \65 years old and older patients
([75 years) had significantly (p\ 0.0001) greater costs
compared to patients aged 65–75 (Table 5). When indi-
vidual comorbidities were added to the model, cancer was
significantly associated with higher baseline costs
(p = 0.003), whereas cardiac ischemia is significantly
associated with lower total costs (p = 0.002; Table 6). The
cost ratio was not impacted when the number of comor-
bidities (cost ratio = 0.95; 95 % CI 0.91–0.99) was added
to the model (as proxies of comorbid severity/medical
complexity) or when combined with the number of con-
comitant meds (cost ratio = 0.97; 95 % CI 0.95–1.00),
despite reaching statistical significance (p B 0.03). In
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a Comorbid conditions
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b Medication use occurring in




c Inclusive of medications for
Alzheimer’s disease
Comorbiditya Medicationsb Number of
medicationsc
Total (N = 2,594)
n (%) n (%) n (%)
Cancer 24 (0.92) Alzheimer’s disease treatments None 146 (5.63)



























24 (0.92) Angiotensin II antagonists 302
(11.64)
Epilepsy 13 (0.50) Antidepressants 756
(29.14)






Diuretics, thiazides, and potassium-
sparing agents
178 (6.86)






Vitamin B12 191 (7.36)
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sensitivity analyses using US unit costs, the association
between cancer and higher costs disappeared, but cardiac
ischemia remained as a predictor of lower costs and
hyperlipidemia was also associated with a lower cost ratio.
The impact of gender, age, and functional status remained
significant.
Discussion
The present analysis looked at the impact of comorbid
conditions in addition to demographics, disease severity,
and number of concomitant medications on baseline costs
in a clinical trial population of patients with mild-to-
moderate AD. The number of comorbidities did not yield
an impact on baseline total costs of care, and combining the
number of comorbid conditions and concomitant medica-
tions to represent comorbid severity had a very nominal
impact on baseline costs. In this analysis, higher costs were
associated with greater functional impairment and are
consistent with similar published analyses [19, 39–41].
Regardless of this unexpected disassociation between total
number of comorbidities and costs, it is important to rec-
ognize that results were dependent on the clinical trial
population studied. Accordingly, there is a benefit in
understanding how findings vary across relevant data
generated from claims analyses, RCTs, and observational
studies.
Comorbidity had a minimal impact on cost, whether
individually or expressed as severity (number of condi-
tions). A more consistent impact of comorbidities on higher
costs of care was hypothesized. Unexpectedly, cardiac
ischemia was a predictor of lower costs, whereas in claims-
based samples, patients with a history of cardiac disease
had higher costs due to more frequent hospitalizations,
preventable hospitalizations, etc. [13]. This suggests that
patients with a history of cardiac ischemia who enroll in
clinical trials potentially represent a subset of patients with
cardiac ischemia who are managed more appropriately and
also who are more responsive to treatments for their
Table 4 Baseline utilization and cost of care
Resource item Baseline (N = 2,594)
Resource utilization Cost
na Meana SD Mean (UK £b) SD
Informal care 2,578 173.47 h/month 243.01 855.19 1,266.62
Informal care (lost production)c 2,578 104.31 h/month 126.35 1,254.82 1,520.02
Accommodation 29 0.06 day/month 1.04 3.81 63.74
Intermediate forms of accommodation 24 0.05 1.03 3.12 61.56
Dementia-specific residential accommodation 6 0 0.04 0.05 2.79
Long-term institutional care (nursing home) 9 0.01 0.16 0.64 16.42
Hospitalization 110 0.05 day/month 0.92 15.99 293.4
Geriatrics 100 0 0.08 0.49 25.05
Psychiatric 103 0.03 0.82 10.94 261.01
Internal medicine 101 0.01 0.41 3.69 129.85
Surgery 100 0 0.08 0.86 24.25
Community care services 2,244 8.61 h/month 52.38 272 1,912.51
District nurse 2,106 0.42 14.29 30.31 1,043.16
Home support worker 2,108 3.3 31.74 95.57 920.38
Home-delivered meals 2,076 0.48 9.31 2.41 46.54
Transportation 2,100 0.55 6.75 4.46 55.03
Total cost of cared – – – 1,146.98 2,483.02
Total cost of care with informal care as all lost productione – – – 1,546.62 2,631.60
N overall sample size, n number of patients in category
a n patients or caregivers reporting any use; mean includes all patients (users and nonusers) with missing values set to zero
b Costs are per subject per month (in UK pounds)
c Lost production is the unadjusted sum of instrumental and personal activities of daily living (PADL) (with a maximum of 540) regardless of
caregiver age 65?
d Total cost of care includes informal care costs using lost leisure time for non-working caregivers (£855.19)
e Total cost of care includes informal care costs using all lost production for non-working caregivers (£1,254.82)
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comorbidities. Additionally, clinical trials are not powered
specifically for economic endpoints or analyses. Due to a
restricted range of comorbidity severity in clinical trials,
the lack of findings may also reflect a general trend of more
medically stable and less medically ill patients with AD
enrolling in clinical trials. This is likely to create a dis-
connect in findings between claims databases, observa-
tional studies, and RCTs in that RCTs are unlikely to
include the heterogeneity of patients found in non-ran-
domized studies. Finally, while the type of comorbidity
impacting cost also varied slightly depending whether UK
or US unit costs were used, this difference did not change
the fact that comorbidity in these analyses was unassoci-
ated with escalated costs.
Baseline rates of comorbid conditions were lower than
those described in claims database studies [13] but con-
sistent with prospective observational studies [11, 14, 42].
Clinical trial populations are generally expected to have
fewer comorbid conditions given the study inclusion/
exclusions criteria for allowable comorbidities and severity
of comorbidities [20]. Baseline costs for RCT populations
may therefore be different from populations in claims
databases or community-based studies in that the popula-
tion sample is not likely to reflect a true distribution of the
Table 5 Baseline
demographics and clinical
predictors for total cost of care
(UK costs)—gamma model
with missing costs
p\ 0.01 shown as bolded text
ADCS-ADL Alzheimer’s disease
cooperative study: activities of
daily living, CDR Clinical
Dementia Rating, CDR-SB
Clinical Dementia Rating-Sum











Gender: male (ref: female) -0.1266 0.0485 0.88 0.80 0.97 0.009
Age: 65–75 (ref: 75?) -0.2334 0.0533 0.79 0.71 0.88 <0.0001
Age: 55-64 (ref: 75?) 0.2951 0.0684 1.34 1.18 1.54 <0.0001
MMSE: mild (20–30) (ref: 10-19) 0.1015 0.0543 1.11 1.0 1.23 0.062
ADCSADL: 68–78 (ref: 0-45) -0.4390 0.0862 0.64 0.55 0.76 <0.0001
ADCSADL: 58–67 (ref: 0-45) -0.6217 0.0829 0.54 0.46 0.63 <0.0001
ADCSADL: 46–57 (ref: 0–45) -0.3481 0.0818 0.71 0.60 0.83 <0.0001
NPI:\10 (ref: 10?) -0.0723 0.0523 0.93 0.84 1.03 0.167
CDR: 0.5–1 (ref: 2?) -0.0064 0.4032 0.99 0.45 2.19 0.987
CDR: 2 (ref:3) 0.0983 0.3876 1.10 0.52 2.36 0.8
CDR-SB: 0.5–9 (ref: 16–18) 0.2876 0.5082 1.33 0.49 3.61 0.571
CDR-SB: 9.5–15.5 (ref: 16–18) 0.4562 0.4952 1.58 0.60 4.17 0.357
Table 6 Baseline
comorbidities as predictors of
total cost of care (UK costs)—
gamma model with missing
costs and comorbidities
Significant p values are shown
as bolded text. Model retained
significant demographic and
clinical predictors of care costs
ADCS-ADL Alzheimer’s disease
cooperative study: activities of
daily living, CI confidence
interval, COPD chronic
obstructive pulmonary disease,
ref reference, UTI urinary tract
infection






Gender: male (ref: female) -0.1365 0.0486 0.87 0.79 0.96 0.005
Age: 65–75 (ref: 75?) -0.2374 0.0536 0.79 0.71 0.88 <0.0001
Age: 55–64 (ref: 75?) 0.2809 0.0696 1.32 1.16 1.52 <0.0001
ADCS-ADL: 68–78 (ref: 0–45) -0.5174 0.0709 0.60 0.52 0.68 <0.0001
ADCS-ADL: 58–67 (ref: 0–45) -0.7223 0.0714 0.49 0.42 0.56 <0.0001
ADCS-ADL: 46–57 (ref: 0–45) -0.4364 0.0762 0.65 0.56 0.75 <0.0001
Cancer 0.7595 0.2580 2.14 1.29 3.54 0.003
COPD -0.1016 0.1770 0.90 0.64 1.28 0.566
Depression 0.0257 0.0566 1.03 0.92 1.15 0.65
Diabetes -0.0387 0.0763 0.96 0.83 1.12 0.612
Hyperlipidemia -0.1144 0.0518 0.89 0.81 0.99 0.027
Hypertension -0.0187 0.0495 0.98 0.89 1.08 0.706
Cardiac ischemia -0.2554 0.0806 0.77 0.66 0.91 0.002
UTI -0.2902 0.2489 0.75 0.46 1.22 0.244
Epilepsy 0.1166 0.3351 1.12 0.58 2.17 0.728
Stroke 0.5269 0.2220 1.69 1.10 2.62 0.018
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severity of comorbid diseases. Furthermore, participation in
18-month AD clinical trials is, in part, contingent upon the
caregiver’s willingness and motivation [7]. Therefore, these
patients may be more clinically stable or better managed,
and may represent a subpopulation without significant other
comorbidities who responded well to therapeutic interven-
tion. It is important to note that, at the time of these clinical
trials, diagnosing a patient as having probable AD required
a rigorous screening of the influence of any comorbidities
on cognitive/functional impairment consistent with the
NINCDS-ADRDA criteria. A selection bias may have been
inadvertently created for patients well enough to participate
or more motivated to participate in trials, or who had not
had any significant exacerbations of medical conditions that
would prevent inclusion in a clinical trial.
A challenge in self-reported methods for comorbidities
in clinical trials is that it does not allow for an easy com-
parison with baseline rates of comorbid disorders within
the healthcare system of interest. If access to actual med-
ical records was included as part of trial consent, this
would provide an opportunity to characterize the similari-
ties and differences of a matched cohort within the same
healthcare system, as well as help to understand baseline
rates of diseases and acute events. Access to claims data
may also eliminate some issues with proxy reporting of
resource utilization, such as unawareness of care use or a
too-long recall period [7, 8]. In addition, pre- and post-trial
trajectories of resources use would be available for ana-
lysis. Claims data has its limitations, however, and
important variables, such as use of community services and
caregiver hours, would still need to be assessed via self/
caregiver reports [43].
Future studies should consider evaluating the impact of
comorbid conditions longitudinally within clinical trial
populations. As demonstrated in claims databases or
community-based studies, costs associated with comorbid
conditions increase over time [9, 12]. Collection of costs
longitudinally at periodic intervals may inform the poten-
tial indicators for some stability of costs over time.
Unfortunately, due to the early discontinuation of treatment
dosing within this trial and subsequent protocol amend-
ment, the reliability and validity of follow-up cost data
were not considered to be of significant enough rigor to
allow for a robust study of longitudinal costs. The available
longitudinal data included variable lengths of follow-up
and forcibly smaller sample sizes at later time points that
would not reflect typical study attrition.
Although conclusive statements about the impact of
comorbidities on costs could not be made with the present
cross-sectional analyses, it is important to note that consis-
tencies with the previous literature were noted, particularly
around the association between greater functional impair-
ment and costs [44]. It is well appreciated in geriatric
medicine that, since elderly patients often have multiple and
varying comorbidities of varying severity, that measures of
function are the most reliable means of predicting outcomes
and costs. As such, perhaps more consistent ways to translate
functional measures (measures captured in clinical trials
fairly reliably) into costs may be the most effective way to
conduct cost-effectiveness studies. It is unclear why excess
costs were not noted, even in AD patients with at least five
comorbidities in the current analyses, since this population is
most often frail and has been demonstrated previously to
consistently have excess costs as the number of comorbidi-
ties rise [9, 12]. This discrepancy suggests that a combination
of sources may be most beneficial when evaluating the cost
and burden of disease as well as the impact of new treatments
on costs of illness. Although the ADCS-ADL is intended to
capture functional impairment due to underlying cognitive
impairment, it is possible that other comorbidities will
impact the rating of the functional scale. Another explana-
tion for the lack of association between comorbidities and
cost in the current analysis is that specific comorbidities,
which were not collected, may have had stronger associa-
tions with cost. Although cost analyses of clinical trial data
may not adequately capture the variability in costs due to
comorbidity-derived subgroups, clinical trial data may give
preliminary indications as to the impact of altering the course
of cognitive and functional decline on costs.
The present analyses offer an important step forward in
understanding how clinical trials may help inform deci-
sions about the overall impact of new therapeutics beyond
traditional regulatory audiences. Notably, there is a paucity
of published literature in AD on cost that has been directly
garnered from clinical trials. Functional ability remains a
consistent predictor of costs in the care of patients with
AD. Comorbidities are likely less informative in deter-
mining variances in baseline costs if looking at clinical trial
populations in isolation. Therefore, it is just as important
for trial sponsors to include resource utilization measures
in their trials as it is for decision makers to allow extrap-
olations beyond the clinical trial to best characterize and
predict the full risk–benefit profile of a new therapeutic
agent. Expanded precision and ease of diagnosis of AD
pathology is also likely to move clinical trial populations
closer to ‘‘typical’’ patient populations as the current par-
adigm shifts away from AD as a rule-out diagnosis.
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